A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Naval Daver; Amandeep Salhotra; Joseph M. Brandwein; Nikolai A. Podoltsev; Daniel A. Pollyea; Joseph G. Jurcic; Sarit Assouline; Karen Yee; Mengsong Li; Tony Pourmohamad; Divya Samineni; Teiko Sumiyoshi; Anjali Vaze; Randall C. Dere; Connie Ma; James Cooper

doi:10.1002/ajh.26136

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Naval Daver, Amandeep Salhotra, Joseph M. Brandwein, Nikolai A. Podoltsev, Daniel A. Pollyea, Joseph G. Jurcic, Sarit Assouline, Karen Yee, Mengsong Li, Tony Pourmohamad, Divya Samineni, Teiko Sumiyoshi, Anjali Vaze, Randall C. Dere, Connie Ma, James Cooper

Leukemia

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	E175-E179
Journal	American journal of hematology
Volume	96
Issue number	5
DOIs	https://doi.org/10.1002/ajh.26136
State	Published - May 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26136

Cite this

Daver, N., Salhotra, A., Brandwein, J. M., Podoltsev, N. A., Pollyea, D. A., Jurcic, J. G., Assouline, S., Yee, K., Li, M., Pourmohamad, T., Samineni, D., Sumiyoshi, T., Vaze, A., Dere, R. C., Ma, C., & Cooper, J. (2021). A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. American journal of hematology, 96(5), E175-E179. https://doi.org/10.1002/ajh.26136

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. / Daver, Naval; Salhotra, Amandeep; Brandwein, Joseph M. et al.
In: American journal of hematology, Vol. 96, No. 5, 01.05.2021, p. E175-E179.

Research output: Contribution to journal › Letter › peer-review

Daver, N, Salhotra, A, Brandwein, JM, Podoltsev, NA, Pollyea, DA, Jurcic, JG, Assouline, S, Yee, K, Li, M, Pourmohamad, T, Samineni, D, Sumiyoshi, T, Vaze, A, Dere, RC, Ma, C & Cooper, J 2021, 'A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia', American journal of hematology, vol. 96, no. 5, pp. E175-E179. https://doi.org/10.1002/ajh.26136

@article{7873d4338dde4b2ab47433ada50f9ca2,

title = "A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia",

author = "Naval Daver and Amandeep Salhotra and Brandwein, {Joseph M.} and Podoltsev, {Nikolai A.} and Pollyea, {Daniel A.} and Jurcic, {Joseph G.} and Sarit Assouline and Karen Yee and Mengsong Li and Tony Pourmohamad and Divya Samineni and Teiko Sumiyoshi and Anjali Vaze and Dere, {Randall C.} and Connie Ma and James Cooper",

note = "Funding Information: We thank the patients and their families who took part in the study, as well as the staff, research coordinators, and investigators at each participating institution. Writing and editing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc. Genentech was involved in the study design, data interpretation, and the decision to submit for publication in conjunction with the authors.",

year = "2021",

month = may,

day = "1",

doi = "10.1002/ajh.26136",

language = "English (US)",

volume = "96",

pages = "E175--E179",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

AU - Daver, Naval

AU - Salhotra, Amandeep

AU - Brandwein, Joseph M.

AU - Podoltsev, Nikolai A.

AU - Pollyea, Daniel A.

AU - Jurcic, Joseph G.

AU - Assouline, Sarit

AU - Yee, Karen

AU - Li, Mengsong

AU - Pourmohamad, Tony

AU - Samineni, Divya

AU - Sumiyoshi, Teiko

AU - Vaze, Anjali

AU - Dere, Randall C.

AU - Ma, Connie

AU - Cooper, James

N1 - Funding Information: We thank the patients and their families who took part in the study, as well as the staff, research coordinators, and investigators at each participating institution. Writing and editing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc. Genentech was involved in the study design, data interpretation, and the decision to submit for publication in conjunction with the authors.

PY - 2021/5/1

Y1 - 2021/5/1

UR - http://www.scopus.com/inward/record.url?scp=85102256163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102256163&partnerID=8YFLogxK

U2 - 10.1002/ajh.26136

DO - 10.1002/ajh.26136

M3 - Letter

C2 - 33617672

AN - SCOPUS:85102256163

SN - 0361-8609

VL - 96

SP - E175-E179

JO - American journal of hematology

JF - American journal of hematology

IS - 5

ER -

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this